Articles On Genetic Signatures (ASX:GSS)

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Genetic Signatures (ASX:GSS) has announced a three-year contract to supply its EasyScreen genetic diagnostic kits and instruments to seven hospitals across Wales.

Genetic Signatures (GSS) has secured a three-year contract with Public Health Wales, worth up to $1.8 million per annum, with an option to extend for two years The contract will see the company supply its EasyScreen diagnostic kits and ins...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

In this week’s ScoPo’s Powerplays, healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, examines the turbulent start to 2022 for ASX health stocks and what could lie ahead as ge...

ShareCafeGenetic Signatures (ASX: GSS) – Webinar Presentation John Melki – CEO & Director – Genetic Signatures is a specialist molecular diagnostics company focused on the development and commercialisation of its proprietary platform...

ShareCafeWebinar Recap – GSS, LGP, ALA & RTH Catch up on the full webinar with presentations from Genetic Signatures (ASX: GSS),  Little Green Pharma (ASX: LGP),  Arovella Therapeutics (ASX: ALA)  & Quantum Graphite (ASX: QG...

At the time of writing, the ASX 200 Health Index (XHJ) is down by 2.3%, while the benchmark ASX 200 is falling by 0.7%. Cannabis stock Little Green Pharma (ASX:LGP) has been awarded an Italian government tender to deliver a shipment of EU G...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. During his Australian Open quar...

Australia’s Therapeutic Goods Administration (TGA) registers a saliva-based protocol for testing samples using Genetic Signatures’ (GSS) 3base EasyScreen detection kit A recent study by scientists in South Africa demonstrated that saliva s...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a decline. At the time of writing, the benchmark index is down 0.1% to 7,447.7 points. Four ASX shares that have not let that hold them back are l...

The Genetic Signatures Ltd (ASX: GSS) share price is on the move today after an update on the company’s COVID-19 test kit. Shares in the diagnostics company are swapping hands at $1.77 in afternoon trade, up 6.31%. Let’s take a look at w...

Among ASX health stocks with news, Genetic Signatures (ASX:GSS) caught the market’s attention with an update on its latest COVID-19 testing product. The diagnostics company confirmed Australia’s health regulator, the Therapeutic Goods Admin...

ASX investors evidently shrugged off omicron fears in December, with the last month of the 2021 being the second best of the year. Ultimately, the market finished 2021 13% higher than it started. Patience pays off, unless you got in at the...

Shares in molecular diagnostics company Genetic Signatures Ltd (ASX: GSS) finished the day strong and closed 12.5% in the green at $1.75. Today’s gain extends an impressive run the company has been on over the past week. Specifically, inv...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

Genetic Signatures (GSS) has released a wide-ranging update, revealing it’s expecting $21 million dollars in sales in 1H 2022 The company has created a new COVID-19 detection kit to differentiate between the Delta and Omicron variants GSS...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week With a slew o...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Power says...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

ShareCafeHidden Gems Webinar Recap – BPH, EX1, RAP & PTX Catch up on the full webinar with presentations from BPH Energy (ASX: BPH), Exopharm (ASX: EX1), RessApp (ASX: RAP) & Prescient Therapeutics (ASX: GSS) Hidden Gems Webinar Re...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

ShareCafeHidden Gems Webinar Recap – PHL, LBY, BCB & GSS Catch up on the full webinar with presentations from Propell Holdings (ASX: PHL), Laybuy (ASX: LBY), Bowen Coking Coal (ASX: BCB) & Genetic Signatures (ASX: GSS) Hidden Gems...

ShareCafeTest kits for infectious disease John Melki – CEO & Director – Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3ba...

ShareCafeGenetic Signatures: Australia’s Rapid Growth Diagnostics Company by Colin Hay   Genetic Signatures’ growth strategy is about building its customer numbers, the range of its proprietary tests for COVID-19 and a range of viral, proto...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Summary Trajan Group Holdings made a strong debut on ASX on June 7, 2021. The MedTech company successfully raised AU$90 million via IPO at a market cap of AU$220 million. The company is expected to achieve revenue of AU$75 million in...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Summary Several ASX-listed companies have released their quarterly results in the last few days, attracting significant market attention. Genetic Signatures reported strong quarterly and YTD sales driven by the increasing demand for it...

Summary Medicinal cannabis player MGC Pharmaceuticals has a historic quarter with the ground-breaking achievement of listing on the LSE. Oncology company Race Oncology has an action-packed quarter with significant progress on the Three...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

ShareCafeThe Week that Was – March 1-5, 2021 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do so, he...

ShareCafeGenetic Signatures Leverages New Screening Targets to EU and US Markets Following the announcement of its first substantial profit (for the first half of full year 2021), GeneticSignatures (ASX: GSS) a specialist molecular diagnost...

The Genetic Signatures Ltd (ASX: GSS) share price was on form on Monday. At one stage the molecular diagnostics company’s shares were up as much as 10% to $1.83. The Genetic Signatures share price ultimately closed the day 6% higher at $1....

ShareCafeGenetic Signatures (ASX:GSS) – Hidden Gems Webinar Presentation – 12/2/21   Presenter – John Melki – Chief Executive Officer and Director – Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the deve...

ShareCafeHidden Gems Webinar Recap – Chester Asset Management, GSS, SVL, BPH – 12/2/21 Catch up on the full webinar with presentations from Chester Asset Management, Genetic Signatures (ASX:GSS), Silver Mines Limited (ASX:SVL) & BPH En...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

The Genetic Signatures Ltd (ASX: GSS) share price has been pushing higher with the market today. In afternoon trade the specialist molecular diagnostics company’s shares are up 3% to $1.96. Though, at one stage today, the Genetic Signature...

Summary Genetic Signatures has acquired Boston Medical Center (BMC) for the supply of its SARS-CoV-2 detection kits. The new agreement will offer BMC with an increased testing capability. The Company also highlighted that the broader...

The Genetic Signatures Ltd (ASX: GSS) share price is rocketing higher on Wednesday after the release of an announcement. In afternoon trade the specialist molecular diagnostics company’s shares are up almost 25% to $2.12. Why is the Geneti...